AVRO - AVROバイオ (AVROBIO Inc.) AVROバイオ

 AVROのチャート


 AVROの企業情報

symbol AVRO
会社名 AVROBIO Inc (AVROバイオ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 AVROBIO Inc. is a clinical stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its product pipeline includes AVR-RD-01 AVR-RD-02 AVR-RD-03 and AVR-RD-04. The Company is developing AVR-RD-01 for the treatment of Fabry disease. AVR-RD-02 is the Company’s gene therapy for Gaucher disease. AVR-RD-03 is being developed for the treatment of Pompe disease. The Company is developing AVR-RD-04 for the treatment of patients with cystinosis.   AVROバイオは米国のバイオ医薬品企業。臨床段階で、主に希少疾患に対する遺伝子治療に焦点を当てた医薬品の開発・商業化に従事する。同社はリソソ―ム蓄積症に対する幹細胞遺伝子治療を開発し、一度の投与で効果を表す医薬品を手がける。パイプラインにはゴ―シェ病、ポンペ病、シスキシン症の治療薬を含む。本社所在地はマサチュ―セッツ州ケンブリッジ。   Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firms clinical-stage programs include Fabry disease, Gaucher disease and cystinosis . The company was founded by Geoff Mackay in 2015 and is headquartered in Cambridge, MA.
本社所在地 One Kendall Square Building 300 Suite 201 Cambridge MA 02139 USA
代表者氏名 Bruce Booth ブルースブース
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 781-962-6030
設立年月日 42309
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 34人
url www.avrobio.com
nasdaq_url https://www.nasdaq.com/symbol/avro
adr_tso
EBITDA EBITDA(百万ドル) -31.03900
終値(lastsale) 25.6
時価総額(marketcap) 612783052.8
時価総額 時価総額(百万ドル) 578.31400
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 423.29900
当期純利益 当期純利益(百万ドル) -35.06700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Avrobio Inc revenues was not reported. Net loss applicable to common stockholders increased from $4.7M to $21M. Higher net loss reflects Research and developme increase from $3.3M to $12.9M (expense) General and administrative increase from $1.2M to $3.9M (expense) Gains/Losses on Trading Derivatives increase from $35K to $1.6M (expense).

 AVROのテクニカル分析


 AVROのニュース

   AVROBIO to Present at Three Upcoming Investor Conferences  2020/09/03 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in three upcoming virtual investor conferences. Citi’s 15th Annual BioPharma Virtual Conference Date: Wednesday, Sept. 9, 2020 2020 Wells Fargo Virtual Healthcare Conference Date: Thursday, Sept. 10, 2020 Time: 4:40 p.m. ET Morgan Sta
   AVROBIO : at the 2020 Wedbush PacGrow Healthcare Conference | MarketScreener  2020/08/12 11:13:06 MarketScreener
Company Presentation Wedbush PacGrow Healthcare Virtual Conference August 2020 Disclaimer … | August 12, 2020
   AVROBIO : Investor Presentation August 2020 | MarketScreener  2020/08/06 11:04:08 MarketScreener
Company Presentation August 2020 Disclaimer This… | August 6, 2020
   AVROBIO Reports Second Quarter 2020 Financial Results and Provides Business Update  2020/08/06 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the second quarter ended June 30, 2020 and provided a business update. “We have continued to progress our clinical trials despite the challenges of the COVID-19 global pandemic and have now dosed 12 patients across four clinical trials, with initial data from the first patient dosed in
   AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  2020/07/08 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 138,200 shares of the company’s common stock to five new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options were gra
   AVROBIO Outlines Response to COVID-19 and Current Assessment of Business Impact  2020/03/30 20:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today shared an update on its response to the COVID-19 pandemic and a current assessment of the impact on AVROBIO’s operations. “Our first priority during this unprecedented time is the health of our employees, our patients and their communities, and the employees of our clinical sites, partners and vendors. In accordance
   AVROBIO to Participate in Upcoming April Investor Conferences  2020/03/26 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team will participate at three upcoming virtual investor conferences: Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day Panel Presentation: Viral Vector Manufacturing: Current State of Play in Industry Time: 8:10 a.m. ET Date: Friday, April 3, 2020 W
   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm  2020/03/17 21:58:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $AVRO #AVRO--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc.
   AVROBIO Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update  2020/03/16 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year ended Dec. 31, 2019 and provided a business update. “For AVROBIO, 2019 was an important year, with positive data on a primary clinical endpoint from the first patient in our Fabry Phase 2 trial and the unveiling of our state-of-the-art gene therapy platform
   AVROBIO Receives Orphan Drug Designation from U.S. FDA for AVR‑RD‑04 for Cystinosis  2020/03/09 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s investigational gene therapy, AVR-RD-04, for the treatment of cystinosis. The gene therapy consists of the patient’s own hematopoietic stem cells, which are genetically modified to express cystinosin, the
   AVROBIO Receives Orphan Drug Designation from U.S. FDA for AVR‑RD‑04 for Cystinosis  2020/03/09 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s investigational gene therapy, AVR-RD-04, for the treatment of cystinosis. The gene therapy consists of the patient’s own hematopoietic stem cells, which are genetically modified to express cystinosin, the
   AVROBIO to Present at the Cowen and Company 40th Annual Health Care Conference  2020/02/24 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the Cowen and Company 40th Annual Health Care Conference at 4:50 p.m. ET on Monday, March 2, 2020, at the Boston Marriott Copley Place, Boston. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors &
   AVROBIO Announces Closing of Underwritten Public Offering  2020/02/18 21:01:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 4,350,000 shares of its common stock. The aggregate gross proceeds to the company from the offering, before deducting underwriting discounts and commission and estimated offering expenses, totaled approximately $100 million. As previously announced, the company has granted the underwriters a 30-day
   AVROBIO Announces Pricing of Underwritten Public Offering of $100 Million of Common Stock  2020/02/13 03:08:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 4,350,000 shares of its common stock at a public offering price of $23.00 per share. Gross proceeds from the underwritten public offering will total approximately $100 million, before deducting underwriting discounts and commissions and other offering expenses payable by the company. In addition, the company has granted
   AVROBIO Presents Positive Initial Data for its Investigational Cystinosis Program and Plato TM Platform, as well as Positive Data Out to 32 Months for its Ongoing Investigational Fabry Program  2020/02/10 21:01:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced new initial data from the first patient dosed in the investigational gene therapy program for cystinosis, showing improvements in early measures at three months compared to baseline. The company also unveiled new clinical data showcasing a sustained biomarker response in patients for up to 32 months after

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 AVROバイオ AVRO AVROBIO Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)